The Jacinto Convit World Organization (JCWO) is a U.S. nonprofit and non-governmental organization incorporated in 2014, that contributes primarily to important areas of public health, such as cancer and infectious diseases in developing countries. JCWO focuses on cancer research and diagnostics through two main programs: Cancer Immunotherapy (CI) and Molecular Diagnostics (MD).
The CI program currently develops a personalized breast cancer therapeutic vaccine, named ConvitVax, designed by Dr. Jacinto Convit during his last years of life. Previous preclinical studies and a small human experience, showed this therapy to be potentially safe and effective, as well as possibly establishing immune system memory. ConvitVax is targeted to underprivileged patients who have very little or no access to new cancer treatments and in some cases to standard of care treatments.
The MD program supports the development and expansion of a personalized, precise and free of cost diagnostic service for various types of cancers and infectious diseases to benefit underprivileged and underserved patients in developing countries who do not have access to these specialized tests. Currently focused on Latin America.